<DOC>
	<DOCNO>NCT01300273</DOCNO>
	<brief_summary>The investigator hypothesize , LPD supplement ketoanalogs reduce urine podocyte loss lower angiotensinogen level urine .</brief_summary>
	<brief_title>Low Protein Diet Supplemented With Ketoanalogs Reducing Proteinuria Maintaining Nutritional Status Type 2 Diabetic Nephropathy</brief_title>
	<detailed_description>Diabetic nephropathy one important cause end stage renal disease world . Recently In multicenter , randomize clinical trial perform China , aim evaluate efficacy safety compound α-keto acid tablet combination low protein diet ( LPD+KA ) delay progress type 2 diabetic nephropathy ( T2DN ) . In study find LPD+KA associated amelioration proteinuria , good reduction loss kidney function compare LPD alone meanwhile nutrition status remain well group ( Role Ketoanalogs diabetic nephropathy—China study , submit publication ) . However , study mechanism underlined effect elucidate This research proposal part continuation study . Restriction Protein intake , strictly control blood pressure , particularly use renin-angiotensin system ( RAS ) blockade show ameliorate proteinuria progression CKD . Podocyte damage know play critical role proteinuria renal function loss A recent study show mRNA expression podocyte marker urinary sediment increase patient T2DN , effect inhibit ACE inhibitor ARB , indicate important role local renal RAS involve damage . Urinary angiotensinogen level good marker situation renal RAS . Consequently investigator propose study effect LPD+KA podocyte well local RAS kidney .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>diagnose type 2 diabetes age range 18 80 year old gender restriction use oral hypoglycemic agent ( limited repaglinide , αglucosidase inhibitor chloroquine ketone ) and/or insulin control blood sugar fast blood sugar high 10mmol/l , glycated hemoglobin high 8.5 % use RAS system blocker ( ACEI ARB ) least 4 week blood pressure high 160/90mmHg . Once enrolled group , dose change , unless contraindication yet start dialysis , GFR base simplify MDRD formula ( 1560 ) ml/min/1.73m2 serum albumin le 25g/l appear dominant proteinuria ( urinary albumin excretion rate &gt; 300mg/24h ) understand willing participate trial sign informed consent compliance poor GFR &lt; 15ml/min/1.73m2 repeat hypercalcemia , hyperkalemia ketoacidosis occur recent 6 month chronic heart failure , NYHA 3 grade combine serious disease 3 month obvious symptom sign liver disease . Alanine aspartate aminotransferase 2 time higher normal severe edema , level nephrotic syndrome serous cavity effusion urinary tract infection urinary tract diseases drug abuser diagnose malignancy receive longterm systemic steroid therapy woman pregnancy Intended pregnancy breastfeed take part clinical drug study 30 day trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Podocyte</keyword>
	<keyword>Low Protein Diet</keyword>
	<keyword>Ketoanalogs</keyword>
</DOC>